Algert Global LLC Has $1.42 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Algert Global LLC raised its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 82.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,630 shares of the company's stock after acquiring an additional 21,975 shares during the period. Algert Global LLC's holdings in Denali Therapeutics were worth $1,417,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Denali Therapeutics by 879.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock valued at $48,000 after buying an additional 1,847 shares in the last quarter. CWM LLC increased its position in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC acquired a new stake in Denali Therapeutics in the 3rd quarter worth about $73,000. Assetmark Inc. boosted its holdings in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after purchasing an additional 580 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock worth $152,000 after purchasing an additional 920 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Price Performance

DNLI stock traded down $0.16 during midday trading on Friday, reaching $25.00. 388,118 shares of the stock were exchanged, compared to its average volume of 1,069,030. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33. The company has a fifty day moving average price of $27.41 and a 200 day moving average price of $24.43. The stock has a market capitalization of $3.60 billion, a PE ratio of -9.12 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the company posted ($0.72) EPS. As a group, analysts anticipate that Denali Therapeutics Inc. will post -2.69 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Ryan J. Watts sold 40,000 shares of the business's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. The trade was a 14.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander O. Schuth sold 15,558 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the sale, the insider now owns 178,066 shares of the company's stock, valued at approximately $5,325,954.06. This trade represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 86,578 shares of company stock valued at $2,474,440. Insiders own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DNLI. Jefferies Financial Group lifted their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Wedbush reduced their target price on Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, August 2nd. Bank of America boosted their price target on Denali Therapeutics from $25.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Citigroup increased their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Finally, Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $38.90.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.